RADX Radiopharm Theranostics Ltd


$ 5.00 $ -0.15 (-2.91 %)    

Tuesday, 28-Oct-2025 10:44:44 EDT
QQQ $ 630.13 $ -0.28 (-0.04 %)
DIA $ 478.02 $ -0.77 (-0.16 %)
SPY $ 686.06 $ -1.03 (-0.15 %)
TLT $ 91.91 $ 0.10 (0.11 %)
GLD $ 363.24 $ 1.51 (0.42 %)
$ 5.275
$ 5.00
$ 4.88 x 100
$ 5.36 x 900
$ 4.85 - $ 5.00
$ 3.50 - $ 50.82
60,439
na
na
$ 0.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from s...

Core News & Articles

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 mil...

Core News & Articles

- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceu...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, &, ldquo, Radiopharm&, rdquo, or the &, ldquo, Company&, rdquo,...

Core News & Articles

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and an...

Core News & Articles

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profileEthics approval and Phase 1...

Core News & Articles

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION